search
Back to results

Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia

Primary Purpose

Pneumonia

Status
Completed
Phase
Phase 3
Locations
Kenya
Study Type
Interventional
Intervention
Amoxicillin
Benzyl penicillin
Sponsored by
KEMRI-Wellcome Trust Collaborative Research Program
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pneumonia focused on measuring Severe pneumonia

Eligibility Criteria

2 Months - 59 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinical signs of WHO-defined severe pneumonia
  • Age 2 months to 59 months

Exclusion Criteria:

  • Clinical signs of WHO-defined very severe pneumonia
  • Clinical or laboratory diagnosis of meningitis
  • Clinical diagnosis of severe malnutrition (marasmus/kwashiorkor)
  • Clinical or laboratory diagnosis of severe anaemia requiring transfusion
  • HIV-exposure on rapid HIV antibody test (only observational data will be collected from these patients)
  • Elimination of signs of severe pneumonia in a child with wheeze after outpatient bronchodilator therapy
  • Chronic condition that may underlie or contribute to a presentation with respiratory distress such as: known chronic renal or cardiac disease, presence of cerebral palsy predisposing child to aspiration/hypostatic pneumonia
  • Established bronchiectasis or congenital abnormality of the lower respiratory tract
  • Upper airway obstruction producing stridor
  • Admission from outpatient clinic specifically for treatment of TB
  • Referral from another inpatient facility following treatment with injectable antibiotics for more than 24 hours or because the initial regimen is considered to have failed
  • Documented history of >48hours treatment with oral amoxicillin
  • Failure to obtain informed consent
  • Penicillin allergy

Sites / Locations

  • Kerugoya District Hospital
  • Embu Provincial General Hospital
  • Kisumu East District Hospital
  • New Nyanza Provincial General Hospital
  • Bungoma District Hospital
  • Mbagathi District Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Amoxicillin 45mg/kg 12 hourly

Benzyl Penicillin 50,000IU/kg 6 hourly

Arm Description

Outcomes

Primary Outcome Measures

Treatment Failure at 48 Hours (Two Full Days After Enrollment)
Development of any signs of very severe pneumonia at any time Hypoxemia defined as SpO2 <85% or <80% for altitude < or ≥1500m respectively measured after minimum of 3 minutes on ambient air Persistent vomiting (occurring within 30 minutes of administration of amoxicillin with failure to retain drug after 3 successive attempts at administration) at any time Clinical diagnosis of new bacterial co-morbid condition requiring revision of antibiotic treatment at any time Lower chest wall indrawing Temperature ≥38◦C Respiratory rate ≥5bpm of admission rate if above age-adjusted normal upper limit

Secondary Outcome Measures

Treatment Failure at or Before Discharge / Day 5 Post Enrollment (Whichever Occurs First)
Treatment failure as defined in the primary outcome measure.
Readmission With Diagnosis of Severe or Very Severe Pneumonia Within 14 Days of Enrollment
Death at or Before Five Days Following Enrollment
Death defined as: in-hospital death occurring at any time after randomisation (recruitment for HIV-exposed participants) or verbal report of death of the enrolled patient from parent/guardian communicated either directly or via telephone conversation.
Outcome (Death/Readmission) at 14 Days as Determined by Telephone or Direct Interview
Definition of death as described in third secondary outcome measure.

Full Information

First Posted
July 12, 2011
Last Updated
January 28, 2015
Sponsor
KEMRI-Wellcome Trust Collaborative Research Program
Collaborators
University of Oxford, London School of Hygiene and Tropical Medicine, University of Nairobi
search

1. Study Identification

Unique Protocol Identification Number
NCT01399723
Brief Title
Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia
Official Title
Amoxicillin Versus Benzyl Penicillin for Severe Childhood Pneumonia Amongst Inpatients: An Open Label Randomised Controlled Non-inferiority Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2015
Overall Recruitment Status
Completed
Study Start Date
September 2011 (undefined)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
September 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
KEMRI-Wellcome Trust Collaborative Research Program
Collaborators
University of Oxford, London School of Hygiene and Tropical Medicine, University of Nairobi

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study seeks to determine whether clinical outcome following initial treatment of severe pneumonia with oral amoxicillin is as effective as the current standard benzyl penicillin. The study will also provide an estimate of the proportion of Kenyan children with severe pneumonia who fail treatment with a single antibiotic.
Detailed Description
Case management for the treatment of childhood acute respiratory infections has been widely promoted in many developing countries for over 20 years. Despite this, pneumonia continues to claim over 1.5 million lives of children under five annually. The use of affordable, easily-administered, safe, effective treatments can potentially reduce the burden of childhood pneumonia. The WHO recommends the use of a single antibiotic for the treatment of severe pneumonia. Whereas in Asia, evidence from large randomized clinical trials has changed policy recommendations for treatment of severe pneumonia from parenteral penicillin to oral amoxicillin, there is little evidence to inform a similar move in African children where pneumonia is associated with poorer outcomes. In this study the investigators will investigate effectiveness of oral amoxicillin versus the current standard treatment, benzyl penicillin in severe childhood pneumonia using a randomized controlled non-inferiority design preceded by a pilot pre-intervention phase. The investigators will also collect observational data HIV-exposed / infected children with severe pneumonia. 594 children aged 2 - 59 months admitted with clinical signs of severe pneumonia to up to 7 hospitals in Kenya will be randomly assigned to receive either oral amoxicillin or injectable benzyl penicillin. They will then be followed up for the primary outcome of pre-defined treatment failure at 48 hours. The results of this trial will provide valuable data on the effectiveness of oral amoxicillin in the treatment of severe pneumonia in a population of Kenyan children and determine the practicability of conducting large pragmatic trials on pneumonia in Africa similar to those done in Asia.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pneumonia
Keywords
Severe pneumonia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
561 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Amoxicillin 45mg/kg 12 hourly
Arm Type
Experimental
Arm Title
Benzyl Penicillin 50,000IU/kg 6 hourly
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Amoxicillin
Intervention Description
Oral 45mg/kg 12 hourly
Intervention Type
Drug
Intervention Name(s)
Benzyl penicillin
Intervention Description
Intravenous 50,000IU/kg 6 hourly
Primary Outcome Measure Information:
Title
Treatment Failure at 48 Hours (Two Full Days After Enrollment)
Description
Development of any signs of very severe pneumonia at any time Hypoxemia defined as SpO2 <85% or <80% for altitude < or ≥1500m respectively measured after minimum of 3 minutes on ambient air Persistent vomiting (occurring within 30 minutes of administration of amoxicillin with failure to retain drug after 3 successive attempts at administration) at any time Clinical diagnosis of new bacterial co-morbid condition requiring revision of antibiotic treatment at any time Lower chest wall indrawing Temperature ≥38◦C Respiratory rate ≥5bpm of admission rate if above age-adjusted normal upper limit
Time Frame
48 hours
Secondary Outcome Measure Information:
Title
Treatment Failure at or Before Discharge / Day 5 Post Enrollment (Whichever Occurs First)
Description
Treatment failure as defined in the primary outcome measure.
Time Frame
Patients will be followed up from the day of hospitalisation (day 0) until the day of medical discharge (average duration of 3 days) or until day 5 of hospitalisation (whichever occurs first).
Title
Readmission With Diagnosis of Severe or Very Severe Pneumonia Within 14 Days of Enrollment
Time Frame
Day 0 to Day 14
Title
Death at or Before Five Days Following Enrollment
Description
Death defined as: in-hospital death occurring at any time after randomisation (recruitment for HIV-exposed participants) or verbal report of death of the enrolled patient from parent/guardian communicated either directly or via telephone conversation.
Time Frame
Day 0 to Day 5
Title
Outcome (Death/Readmission) at 14 Days as Determined by Telephone or Direct Interview
Description
Definition of death as described in third secondary outcome measure.
Time Frame
Day 14

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Months
Maximum Age & Unit of Time
59 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical signs of WHO-defined severe pneumonia Age 2 months to 59 months Exclusion Criteria: Clinical signs of WHO-defined very severe pneumonia Clinical or laboratory diagnosis of meningitis Clinical diagnosis of severe malnutrition (marasmus/kwashiorkor) Clinical or laboratory diagnosis of severe anaemia requiring transfusion HIV-exposure on rapid HIV antibody test (only observational data will be collected from these patients) Elimination of signs of severe pneumonia in a child with wheeze after outpatient bronchodilator therapy Chronic condition that may underlie or contribute to a presentation with respiratory distress such as: known chronic renal or cardiac disease, presence of cerebral palsy predisposing child to aspiration/hypostatic pneumonia Established bronchiectasis or congenital abnormality of the lower respiratory tract Upper airway obstruction producing stridor Admission from outpatient clinic specifically for treatment of TB Referral from another inpatient facility following treatment with injectable antibiotics for more than 24 hours or because the initial regimen is considered to have failed Documented history of >48hours treatment with oral amoxicillin Failure to obtain informed consent Penicillin allergy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ambrose Agweyu, MSc
Organizational Affiliation
Kemri- Wellcome Trust Research Programme, Nairobi, Kenya
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Elizabeth Obimbo, MMed
Organizational Affiliation
Department of Paediatrics and Child Health, University of Nairobi, Nairobi, Kenya
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Roma Chilengi, MD
Organizational Affiliation
Centre for Infectious Disease Research, Zambia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Tansy Edwards, MSc
Organizational Affiliation
London School of Hygiene and Tropical Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mike English, MD
Organizational Affiliation
Kemri - Wellcome Trust Research Programme, Nairobi, Kenya
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kerugoya District Hospital
City
Kerugoya
State/Province
Central
Country
Kenya
Facility Name
Embu Provincial General Hospital
City
Embu
State/Province
Eastern
Country
Kenya
Facility Name
Kisumu East District Hospital
City
Kisumu
State/Province
Nyanza
Country
Kenya
Facility Name
New Nyanza Provincial General Hospital
City
Kisumu
State/Province
Nyanza
Country
Kenya
Facility Name
Bungoma District Hospital
City
Bungoma
State/Province
Western
Country
Kenya
Facility Name
Mbagathi District Hospital
City
Nairobi
Country
Kenya

12. IPD Sharing Statement

Citations:
PubMed Identifier
25550349
Citation
Agweyu A, Gathara D, Oliwa J, Muinga N, Edwards T, Allen E, Maleche-Obimbo E, English M; Severe Pneumonia Study Group. Oral amoxicillin versus benzyl penicillin for severe pneumonia among kenyan children: a pragmatic randomized controlled noninferiority trial. Clin Infect Dis. 2015 Apr 15;60(8):1216-24. doi: 10.1093/cid/ciu1166. Epub 2014 Dec 30.
Results Reference
derived

Learn more about this trial

Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia

We'll reach out to this number within 24 hrs